Pacific Biosciences EBITDA vs. Current Valuation

PACB Stock  USD 2.08  0.25  13.66%   
Based on Pacific Biosciences' profitability indicators, Pacific Biosciences of may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Pacific Biosciences' ability to earn profits and add value for shareholders.
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-277.3 M
Current Value
-263.4 M
Quarterly Volatility
100.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
The current year's EV To Sales is expected to grow to 16.98, whereas Price To Sales Ratio is forecasted to decline to 11.79. At present, Pacific Biosciences' Accumulated Other Comprehensive Income is projected to decrease significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 17.1 M, whereas Operating Income is projected to grow to (317.7 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.290.2632
Significantly Up
Very volatile
For Pacific Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pacific Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pacific Biosciences of utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pacific Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pacific Biosciences of over time as well as its relative position and ranking within its peers.
  

Pacific Biosciences' Revenue Breakdown by Earning Segment

Check out Your Equity Center.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.46)
Revenue Per Share
0.64
Quarterly Revenue Growth
(0.28)
Return On Assets
(0.11)
Return On Equity
(0.65)
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Pacific Biosciences Current Valuation vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Pacific Biosciences's current stock value. Our valuation model uses many indicators to compare Pacific Biosciences value to that of its competitors to determine the firm's financial worth.
Pacific Biosciences of is regarded fourth in ebitda category among its peers. It is regarded third in current valuation category among its peers . At present, Pacific Biosciences' EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pacific Biosciences' earnings, one of the primary drivers of an investment's value.

Pacific Biosciences' Earnings Breakdown by Geography

Pacific Current Valuation vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Pacific Biosciences

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(277.28 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Pacific Biosciences

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
988.2 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Pacific Current Valuation vs Competition

Pacific Biosciences of is regarded third in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 7.31 Billion. Pacific Biosciences retains roughly 988.2 Million in current valuation claiming about 14% of equities under Health Care industry.

Pacific Biosciences Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Pacific Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pacific Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Pacific Biosciences' change in net profit over the period of time. It can combine multiple indicators of Pacific Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income219 K229.9 K
Operating Income-334.5 M-317.7 M
Income Before Tax-318.2 M-302.3 M
Total Other Income Expense Net16.3 M17.1 M
Net Loss-306.7 M-291.4 M
Income Tax Expense-11.4 M-12 M
Net Loss-309.1 M-293.6 M
Non Operating Income Net Other107 K101.6 K
Net Loss-282.8 M-268.7 M
Interest Income2.3 M2.3 M
Net Interest Income-14.4 M-13.7 M
Change To Netincome100.1 M105.1 M
Net Loss(1.21)(1.27)
Income Quality 0.84  0.90 
Net Income Per E B T 0.96  0.70 

Pacific Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Pacific Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pacific Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pacific Biosciences' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Pacific Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run ETFs Now

   

ETFs

Find actively traded Exchange Traded Funds (ETF) from around the world
All  Next Launch Module

Use Investing Themes to Complement your Pacific Biosciences position

In addition to having Pacific Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Restaraunts Hotels Motels Thematic Idea Now

Restaraunts Hotels Motels
Restaraunts Hotels Motels Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Restaraunts Hotels Motels theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaraunts Hotels Motels Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:
To fully project Pacific Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Pacific Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Pacific Biosciences' income statement, its balance sheet, and the statement of cash flows.
Potential Pacific Biosciences investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Pacific Biosciences investors may work on each financial statement separately, they are all related. The changes in Pacific Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pacific Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.